Rezdiffra (Resmetirom) Cost vs. Alternatives: A Full Comparison for MASH Treatment

What resmetirom is, and what it is not

Resmetirom is the generic name for Rezdiffra, an oral, once-daily tablet and a selective agonist of thyroid hormone receptor beta (THR-beta), a receptor concentrated in liver tissue. It is not a GLP-1 receptor agonist, not a PPAR agonist, and not related to compounded thyroid hormone products. The FDA approved it in March 2024 specifically for adults with MASH and moderate-to-advanced liver fibrosis (F2-F3), to be used alongside diet and exercise, an on-label indication supported by a phase 3 registration trial. That regulatory status is the single biggest differentiator between resmetirom and every alternative discussed below, all of which are used off-label for MASH regardless of how strong their supporting trial data looks.

How it works

By activating THR-beta selectively, without significant stimulation of THR-alpha (the receptor responsible for the cardiac and bone effects of systemic thyroid hormone), resmetirom is designed to increase hepatic fatty acid oxidation and reduce lipogenesis in the liver. This liver-selective mechanism is what separates it from older thyroid hormone analogs abandoned decades ago for tachycardia and bone loss. The manufacturer's prescribing information also describes reductions in LDL cholesterol and triglycerides at approved doses. Thyroid function testing (TSH, free T4) is recommended at baseline and again during the first months of treatment, reflecting a class-level caution even though resmetirom is designed to spare thyroid-related side effects. The core pharmacology and approved indication can be verified against the FDA label.

Resmetirom (Rezdiffra) is FDA-approved specifically for adults with noncirrhotic MASH and stage F2-F3 fibrosis, based on a phase 3 trial that met both co-primary histologic endpoints, MASH resolution without worsening of fibrosis, and fibrosis improvement without worsening of disease activity, at 52 weeks. No other drug on the market currently holds this indication; pioglitazone, vitamin E, and semaglutide are used off-label for MASH based on trial evidence in overlapping but not identical populations, and pipeline agents such as lanifibranor, survodutide, and pegozafermin remain investigational. Readers evaluating cost against alternatives should treat this regulatory distinction, not price alone, as the first filter.

What the approval trial showed, and what needs verification

Resmetirom's approval rested on a large, randomized, double-blind, placebo-controlled phase 3 trial in adults with biopsy-confirmed MASH and fibrosis stages spanning F1B through F3. The trial reported that a meaningfully higher proportion of resmetirom-treated patients achieved MASH resolution without worsening fibrosis, and fibrosis improvement without worsening disease activity, compared with placebo at 52 weeks, with the higher of the two approved doses showing numerically larger effects. Diarrhea and nausea were reported more often than with placebo, generally within the first 12 weeks and generally mild to moderate.

The precise percentages reported in press coverage and the source material for this comparison (roughly 25 to 30% MASH resolution vs. roughly 10% for placebo) are consistent with what has been publicly reported about this trial, but this draft could not independently re-verify the exact figures against a confirmed primary source, since the inherited citation identifiers could not be validated. Anyone relying on exact numbers for a clinical or coverage decision should pull the original trial publication and the FDA label directly rather than citing secondhand figures.

What is established: resmetirom met its co-primary histologic endpoints in the approval trial and received FDA approval for F2-F3 MASH. What is not established: whether the histologic improvements seen at 52 weeks translate into reduced rates of cirrhosis, liver transplant, or death, and how long treatment needs to continue. A dedicated outcomes trial in patients with MASH-related compensated cirrhosis is underway and is expected to address this gap; until it reports, cost-effectiveness arguments for resmetirom rest on a surrogate endpoint, not a hard clinical outcome.

What Rezdiffra costs, and what patients likely pay

Rezdiffra's wholesale acquisition cost has been publicly reported at roughly $47,400 per year. Two things narrow that number for an individual patient, and both are date-sensitive, so confirm current terms before relying on them:

• The manufacturer has operated a copay assistance program for commercially insured patients, which can substantially lower out-of-pocket cost for eligible patients. Program terms and eligibility change and should be confirmed directly with the manufacturer or pharmacy.
• Medicare Part D beneficiaries are subject to the Inflation Reduction Act's annual out-of-pocket cap, which took effect in January 2025 and limits Part D out-of-pocket drug spending to $2,000 per year (payable in monthly installments through the Medicare Prescription Payment Plan). For a Medicare patient prescribed Rezdiffra, this cap, not the list price, is usually the more relevant number.

Commercial insurers and Medicare Part D plans commonly require prior authorization documenting F2-F3 fibrosis, either by liver biopsy or by validated noninvasive testing (for example, transient elastography plus an elevated FIB-4 score). Some plans still require biopsy specifically, which can be a real access barrier given that noninvasive staging is now standard practice in many hepatology clinics. Medicaid coverage varies by state and, as of early 2026, several state formularies have classified Rezdiffra as non-preferred or not yet covered, reportedly pending further outcomes data, this is a state-by-state, time-sensitive fact that should be confirmed against the specific state's current Medicaid formulary.

A published cost-effectiveness assessment reportedly concluded that resmetirom's price falls within commonly used cost-effectiveness thresholds only if the liver-related benefits seen at 52 weeks hold up over time. This is a reasonable description of how such assessments are typically framed for a drug approved on a surrogate endpoint, but the specific report referenced in earlier source material could not be verified here and should be checked directly before being cited as a specific finding.

Off-label alternatives: what they cost and what supports them

No other drug currently carries an FDA indication for MASH. The following are used off-label, based on trial evidence in overlapping (not identical) patient populations, and guideline bodies such as the American Association for the Study of Liver Diseases have weighed in on some of them.

Pioglitazone is a generic thiazolidinedione approved for type 2 diabetes, costing on the order of $10 to 20 per month. A well-known randomized trial in patients with prediabetes or diabetes and biopsy-proven NASH reported meaningfully higher rates of MASH resolution with pioglitazone than placebo over roughly two years of treatment. Its real-world limitations are substantial: weight gain, increased fracture risk in postmenopausal women, and an FDA boxed warning for congestive heart failure. Because MASH disproportionately affects people with metabolic syndrome, these side effects are not trivial exclusions for many candidates.

Vitamin E (commonly dosed at 800 IU daily in trials) is available over the counter for well under $100 per year. The same trial tradition that studied pioglitazone also studied high-dose vitamin E in non-diabetic patients with NASH and reported a benefit over placebo. Separately, a widely cited meta-analysis raised concern about increased all-cause mortality at high vitamin E doses, and a large prostate cancer prevention trial reported a small increase in prostate cancer risk with vitamin E supplementation. These are legitimate reasons some clinicians are cautious about recommending indefinite high-dose vitamin E, particularly in men. AASLD practice guidance has described vitamin E as an option to consider in selected non-diabetic patients rather than a first-line MASH therapy.

Semaglutide (the GLP-1 receptor agonist marketed as Wegovy/Ozempic, depending on dose and indication) is not FDA-approved for MASH as of this writing, though it is approved for obesity and type 2 diabetes. A phase 2 trial in MASH reported a higher rate of MASH resolution with semaglutide 2.4 mg weekly than placebo, but did not meet its fibrosis-improvement endpoint. A larger phase 3 MASH-specific trial has reportedly produced positive topline results, which could support a future label expansion, but full peer-reviewed results and any label change should be confirmed before treating semaglutide as MASH-approved. At current pricing, semaglutide 2.4 mg typically runs well over $1,000 per month without insurance, which is a meaningful fraction of Rezdiffra's annual cost even though it is prescribed for a different indication. Its main practical advantage is treating obesity, glycemic control, and cardiovascular risk simultaneously, relevant given how often these conditions cluster with MASH.

Pipeline drugs: not yet an alternative, not yet priced

Lanifibranor (a pan-PPAR agonist), survodutide (a dual GLP-1/glucagon receptor agonist), and pegozafermin (an engineered FGF21 analog) are all in phase 3 development for MASH as of this writing, per public trial registries (search current status at clinicaltrials.gov). Early-phase trials for each reported meaningful histologic benefit alongside notable side effects, weight gain with lanifibranor's PPAR-gamma activity, high gastrointestinal-related dropout rates with survodutide's higher doses. None has a set price, and none is an available alternative today. Treat any specific efficacy percentage for these agents as provisional until the phase 3 results are published and independently verifiable.

Choosing between available options

This table is a starting framework for a conversation with a hepatologist or gastroenterologist, not a substitute for one. Fibrosis stage, biopsy versus noninvasive staging, diabetes status, weight, cardiovascular risk, and insurance formulary rules all interact, and a clinician managing the patient's full picture may reasonably choose differently than this table alone would suggest.

The cost question underneath the cost question

The reason a straightforward price comparison is misleading is that resmetirom and its off-label competitors are not interchangeable options answering the same question. Resmetirom's price buys a specific regulatory status and a trial designed and powered for FDA approval in a defined fibrosis population. Pioglitazone and vitamin E buy low cost and older trial data in overlapping but not identical populations, without regulatory backing for MASH. Semaglutide buys broader metabolic benefit at a price closer to resmetirom's than to pioglitazone's, without a MASH label yet. None of this resolves whether resmetirom's histologic benefit will hold up as a reduction in hard liver outcomes, that is a genuinely open question, not a marketing gap, and it is reasonable for a patient or clinician to weigh it heavily when the annual cost difference between options can exceed $40,000.

When to seek urgent care

MASH treatment decisions are not urgent in the sense of requiring same-day action, but signs of decompensated liver disease are: new or worsening jaundice, confusion, abdominal swelling, black or bloody stools, or significant unexplained bruising or bleeding warrant prompt medical evaluation rather than waiting for a routine follow-up, regardless of which MASH medication a patient is or is not taking.